Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral (for Pazopanib), Intravenous (for Paclitaxel), Intravenous (for Carboplatin)
01
Overview
**pazopanib + paclitaxel + carboplatin** is a combination regimen used in investigational cancer therapy, comprising an oral angiogenesis inhibitor (**pazopanib**), a microtubule stabilizer (**paclitaxel**), and a platinum-based DNA crosslinker (**carboplatin**). Pazopanib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-Kit, thus blocking tumor angiogenesis; paclitaxel promotes microtubule stabilization, causing mitotic arrest; and carboplatin forms DNA adducts leading to apoptosis. This combination has been tested primarily for advanced solid tumors, gynecologic cancers, and other malignancies, but is associated with substantial myelotoxicity and pharmacokinetic interactions, notably due to pazopanib increasing paclitaxel and carboplatin exposure[1][2][4][7].
- Brand names
- Votrient (for pazopanib)Taxol (for paclitaxel)Paraplatin (for carboplatin)
- Other names
- pazopanib + paclitaxel + carboplatinVotrient + Taxol + Paraplatin
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)LCK (Proto-oncogene tyrosine-protein kinase Lck)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR3 (Vascular endothelial growth factor receptor 3)UGT1A1 (UDP-glucuronosyltransferase 1A1)FGFR3 (Fibroblast growth factor receptor 3)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)ITK (Interleukin 2-inducible T-cell kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on pazopanib + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + paclitaxel + carboplatin.